Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study

By sjmartinez • May 3, 2024

Rastogi A, Pollack CV Jr, Sánchez Lázaro IJ, Lesén E, Arnold M, Franzén S, Allum A, Hernández I, Murohara T, Kanda E. Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study. Clin Kidney J. 2024 Mar 25;17(5):sfae083. doi: 10.1093/ckj/sfae083. PMID: 38699484; PMCID: PMC11062025.

Tags: Chronic kidney disease, heart failure, hyperkalaemia, Nephrology, Publications, renin–angiotensin–aldosterone system inhibitor, sodium zirconium cyclosilicate

A case of adrenal insufficiency after initiation of targeted-release budesonide formulation (Nefecon) in a patient with IgA nephropathy

Laxamana TD, Fervenza FC, Glassock RJ, Zand L. A case of adrenal insufficiency after initiation of targeted-release budesonide formulation (Nefecon) in a patient with IgA[...]

Is Obinutuzumab the Answer to Primary Membranous Nephropathy Resistant to Rituximab?

Giri K, Glassock RJ, Fervenza FC. Is Obinutuzumab the Answer to Primary Membranous Nephropathy Resistant to Rituximab? Kidney Int Rep. 2026 Mar 4;11(4):106416. doi: 10.1016/j.ekir.2026.106416.[...]

Discharge criteria from nephrology follow-up back to primary care in modern-era CKD: a review of main guidelines

Oliva-Damaso N, Martinez-Palma L, Oliva-Damaso E, Payan J, Glassock RJ. Discharge criteria from nephrology follow-up back to primary care in modern-era CKD: a review of[...]